Mechanisms of resistance to ionizing radiation in rectal cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Koness RJ, Vezeridis MP et al. Pelvic resection of recurrent rectal cancer. Ann. Surg.220, 586–595 (1994).
   PubMed Web of Science ®Google Scholar
• Chari RS, Tyler DS, Anscher MS et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann. Surg.221, 778–786 (1995).
   PubMed Web of Science ®Google Scholar
• Morino M, Parini U, Allaix M. E et al. Male sexual and urinary function after laparoscopic total mesorectal excision. Surg. Endosc.23(6), 1233–1240 (2008).
   PubMed Web of Science ®Google Scholar
• NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA264, 1444–1450 (1990).
   PubMed Web of Science ®Google Scholar
• Wong RK, Tandan V, De Silva S et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst. Rev.CD002102 (2007).
   Google Scholar
• Gerard A, Buyse M, Nordlinger B et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann. Surg.208, 606–614 (1988).
   PubMed Web of Science ®Google Scholar
• Goldberg PA, Nicholls RJ, Porter NH et al. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur. J. Cancer30A, 1602–1606 (1994).
   PubMed Web of Science ®Google Scholar
• Marks G, Mohiuddin M, Borenstein BD. Preoperative radiation therapy and sphincter preservation by the combined abdominotranssacral technique for selected rectal cancers. Dis. Colon Rectum28, 565–571 (1985).
   PubMed Web of Science ®Google Scholar
• Minsky BD, Cohen AM, Enker WE et al. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int. J. Radiat. Oncol. Biol. Phys.31, 553–559 (1995).
   PubMed Web of Science ®Google Scholar
• Carraro S, Roca EL, Cartelli C et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a Phase II IATTGI study. Int. J. Radiat. Oncol. Biol. Phys.54, 397–402 (2002).
   PubMed Web of Science ®Google Scholar
• Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol.24, 668–674 (2006).
   PubMed Web of Science ®Google Scholar
• Chen ET, Mohiuddin M, Brodovsky H et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int. J. Radiat. Oncol. Biol. Phys.30, 169–175 (1994).
   PubMed Web of Science ®Google Scholar
• De Paoli A, Chiara S, Luppi G et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric Phase II study. Ann. Oncol.17, 246–251 (2006).
   PubMedGoogle Scholar
• Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol.20, 3983–3991 (2002).
   PubMed Web of Science ®Google Scholar
• Grann A, Minsky BD, Cohen AM et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis. Colon Rectum40, 515–522 (1997).
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim JS, Cho MJ et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.54, 403–408 (2002).
   PubMed Web of Science ®Google Scholar
• Krishnan S, Janjan NA, Skibber J. M et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.66, 762–771 (2006).
   PubMed Web of Science ®Google Scholar
• Machiels JP, Sempoux C, Scalliet P et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann. Oncol.18, 738–744 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta VK, Cho C, Ford JM et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.55, 132–137 (2003).
   PubMed Web of Science ®Google Scholar
• Mohiuddin M, Winter K, Mitchell E et al. Randomized Phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J. Clin. Oncol.24, 650–655 (2006).
   PubMed Web of Science ®Google Scholar
• Moore HG, Riedel E, Minsky BD et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann. Surg. Oncol.10, 80–85 (2003).
   PubMed Web of Science ®Google Scholar
• Navarro M, Dotor E, Rivera F et al. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.66, 201–205 (2006).
   PubMed Web of Science ®Google Scholar
• Onaitis MW, Noone RB, Fields R et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann. Surg. Oncol.8, 801–806 (2001).
   PubMed Web of Science ®Google Scholar
• Rich TA, Skibber JM, Ajani JA et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.32(4), 1025–1029 (1995).
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J. Clin. Oncol.21(16), 3098–3104 (2003).
   PubMed Web of Science ®Google Scholar
• Rodel C, Liersch T, Hermann R. M et al. Multicenter Phase II trial of chemoradiation with oxaliplatin for rectal cancer. J. Clin. Oncol.25, 110–117 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan DP, Niedzwiecki D, Hollis D et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J. Clin. Oncol.24, 2557–2562 (2006).
   PubMed Web of Science ®Google Scholar
• Voelter V, Zouhair A, Vuilleumier H et al. CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a Phase II. Br. J. Cancer95(6), 710–716 (2006).
   PubMed Web of Science ®Google Scholar
• Willeke F, Horisberger K, Kraus-Tiefenbacher U et al. A Phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br. J. Cancer96, 912–917 (2007).
   PubMed Web of Science ®Google Scholar
• Willett CG, Hagan M, Daley W et al. Changes in tumor proliferation of rectal cancer induced by preoperative 5-fluorouracil and irradiation. Dis. Colon Rectum41, 62–67 (1998).
   PubMed Web of Science ®Google Scholar
• Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death. Differ.15, 1153–1162 (2008).
   PubMed Web of Science ®Google Scholar
• Willett CG, Warland G, Hagan MP et al. Tumor proliferation in rectal cancer following preoperative irradiation. J. Clin. Oncol.13, 1417–1424 (1995).
   PubMed Web of Science ®Google Scholar
• Willett CG, Warland G, Cheek R et al. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. J. Clin. Oncol.12, 679–682 (1994).
   PubMed Web of Science ®Google Scholar
• Willett CG, Warland G, Coen J et al. Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. Int. J. Radiat. Oncol. Biol. Phys.32, 57–61 (1995).
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Papadopoulos T et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.52, 294–303 (2002).
   PubMed Web of Science ®Google Scholar
• Desai GR, Myerson RJ, Higashikubo R et al. Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Dis. Colon Rectum39, 1090–1096 (1996).
   PubMed Web of Science ®Google Scholar
• Qiu H, Sirivongs P, Rothenberger M et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis. Colon Rectum43, 451–459 (2000).
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Nusslein S, Fietkau R et al. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.41, 585–591 (1998).
   PubMed Web of Science ®Google Scholar
• Lowe SW, Schmitt EM, Smith SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature362, 847–849 (1993).
   PubMed Web of Science ®Google Scholar
• Bracey TS, Miller JC, Preece A et al. g-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene10, 2391–2396 (1995).
   PubMed Web of Science ®Google Scholar
• Merritt AJ, Potten CS, Kemp CJ et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res.54, 614–617 (1994).
   PubMed Web of Science ®Google Scholar
• Spitz FR, Nguyen D, Skibber J. M et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res.2, 1665–1671 (1996).
   PubMed Web of Science ®Google Scholar
• Hendry JH, Cai WB, Roberts SA et al. p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat. Res.148, 254–259 (1997).
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Nelson WG, Slebos RJ et al. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res.53, 4164–4168 (1993).
   PubMed Web of Science ®Google Scholar
• Ribeiro JC, Barnetson AR, Fisher RJ et al. Relationship between radiation response and p53 status in human bladder cancer cells. Int. J .Radiat. Biol.72, 11–20 (1997).
   PubMed Web of Science ®Google Scholar
• Adell G, Sun XF, Stal O et al. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother. Oncol.51, 169–174 (1999).
   PubMed Web of Science ®Google Scholar
• Hamada M, Fujiwara T, Hizuta A et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol.122, 360–365 (1996).
   PubMed Web of Science ®Google Scholar
• Nehls O, Klump B, Holzmann K et al. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer85, 2541–2548 (1999).
   PubMed Web of Science ®Google Scholar
• Elsaleh H, Robbins P, Joseph D et al. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother. Oncol.56, 239–244 (2000).
   PubMed Web of Science ®Google Scholar
• Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev.4, 1–8 (1990).
   PubMed Web of Science ®Google Scholar
• Baas IO, van den Berg FM, Mulder JW et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J. Pathol.178, 264–267 (1996).
   PubMed Web of Science ®Google Scholar
• Finlay CA, Hinds PW, Tan TH et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70–p53 complex with an altered half-life. Mol. Cell Biol.8, 531–539 (1988).
   PubMed Web of Science ®Google Scholar
• Kandioler D, Zwrtek R, Ludwig C et al.TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann. Surg.235, 493–498 (2002).
   PubMed Web of Science ®Google Scholar
• Scott N, Hale A, Deakin M et al. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur. J. Surg. Oncol.24, 169–173 (1998).
   PubMedGoogle Scholar
• Vidaurreta M, Maestro ML, Sanz-Casla MT et al. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int. J. Colorectal Dis.23, 581–586 (2008).
   PubMed Web of Science ®Google Scholar
• Namba H, Hara T, Tukazaki T et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res.55, 2075–2080 (1995).
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell75, 817–825 (1993).
   PubMed Web of Science ®Google Scholar
• Waldman T, Lengauer C, Kinzler KW et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature381, 713–716 (1996).
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Chandrasekaran C, Gordon JI et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature377, 552–557 (1995).
   PubMed Web of Science ®Google Scholar
• Fu CG, Tominaga O, Nagawa H et al. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis. Colon Rectum41, 68–74 (1998).
   PubMed Web of Science ®Google Scholar
• Palazzo JP, Kafka NJ, Grasso L et al. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum. Pathol.28, 1189–1195 (1997).
   PubMed Web of Science ®Google Scholar
• Lin LC, Lee HH, Hwang WS et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg. Oncol.15, 211–216 (2006).
   PubMed Web of Science ®Google Scholar
• Esposito G, Pucciarelli S, Alaggio R et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann. Surg. Oncol.8, 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res.60, 679–684 (2000).
   PubMed Web of Science ®Google Scholar
• Huerta S, Goulet EJ, Huerta-Yepez S et al. Screening and detection of apoptosis. J. Surg. Res.139, 143–156 (2007).
   PubMed Web of Science ®Google Scholar
• Huerta S.Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn.8, 277–288 (2008).
   PubMed Web of Science ®Google Scholar
• Rodel C, Haas J, Groth A et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int. J. Radiat. Oncol. Biol. Phys.55, 1341–1347 (2003).
   PubMed Web of Science ®Google Scholar
• de Bruin EC, van de Velde CJ, van de Pas S et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin. Cancer Res.12, 6432–6436 (2006).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Ruan SB, Cleary KR et al.bcl2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res.55, 237–241 (1995).
   PubMed Web of Science ®Google Scholar
• Anguiano-Hernandez YM, Chartier A, Huerta S. Smac/DIABLO and colon cancer. Anticancer Agents Med. Chem.7, 467–473 (2007).
   PubMed Web of Science ®Google Scholar
• Russo SM, Tepper JE, Baldwin AS Jr et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys.50, 183–193 (2001).
   PubMed Web of Science ®Google Scholar
• Rodel F, Hoffmann J, Grabenbauer GG et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther. Onkol.178, 426–435 (2002).
   PubMed Web of Science ®Google Scholar
• Rodel F, Hoffmann J, Distel L et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res.65, 4881–4887 (2005).
   PubMed Web of Science ®Google Scholar
• Rodel F, Frey B, Leitmann W et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int. J. Radiat. Oncol. Biol. Phys.71, 247–255 (2008).
   PubMed Web of Science ®Google Scholar
• Sarela AI, Scott N, Ramsdale J et al. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol.8, 305–310 (2001).
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer8, 425–437 (2008).
   PubMed Web of Science ®Google Scholar
• Amaya H, Tanigawa N, Lu C et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett.119, 227–235 (1997).
   PubMed Web of Science ®Google Scholar
• Kang SM, Maeda K, Onoda N et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int. J. Cancer74, 502–507 (1997).
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Aklyama S, Yamada K et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer78, 226–231 (1996).
   PubMed Web of Science ®Google Scholar
• Tanigawa N, Amaya H, Matsumura M et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res.57, 1043–1046 (1997).
   PubMed Web of Science ®Google Scholar
• Citrin D, Menard C, Camphausen K.Combining radiotherapy and angiogenesis inhibitors: clinical trial design. Int. J. Radiat. Oncol. Biol. Phys.64, 15–25 (2006).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57, 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrara N.Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol.29, 10–14 (2002).
   PubMed Web of Science ®Google Scholar
• Simpson D, Dunn C, Curran M et al. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs63, 2127–2156 (2003).
   PubMed Web of Science ®Google Scholar
• Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int. J. Radiat. Oncol. Biol. Phys.68, 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10, 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J. Clin. Oncol.23, 8136–8139 (2005).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25, 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26, 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol.19, 717–723 (2008).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol.25, 3238–3245 (2007).
   PubMed Web of Science ®Google Scholar
• Bengala C, Bettelli S, Bertolini F et al. Epidermal growth factor receptor gene copy number K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann. Oncol. (2008).
   PubMedGoogle Scholar
• Bertolini F, Bengala C, Losi L et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys.68, 1455–1461 (2007).
   PubMed Web of Science ®Google Scholar
• Jakob C, Liersch T, Meyer W et al. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J. Gastroenterol.14, 1060–1066 (2008).
   PubMed Web of Science ®Google Scholar
• Liersch T, Langer C, Ghadimi BM et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J. Clin. Oncol.24, 4062–4068 (2006).
   PubMed Web of Science ®Google Scholar
• Ghadimi BM, Grade M, Difilippantonio MJ et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol.23, 1826–1838 (2005).
   PubMed Web of Science ®Google Scholar
• Stoehlmacher J, Goekkurt E, Mogck U et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett.272, 221–225 (2008).
   PubMed Web of Science ®Google Scholar
• Ho-Pun-Cheung A, Assenat E, Thezenas S et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.68, 1094–1101 (2007).
   PubMed Web of Science ®Google Scholar